Neupogen (Filgrastim) for Breast Cancer

Overview
Neupogen is a prescription drug approved by the Food and Drug Administration (FDA) to help prevent febrile neutropenia (a lack of white blood cells, plus fever). If your white blood cell count is low due to chemotherapy for breast cancer, your doctor may prescribe Neupogen. Neupogen is also referred to by its drug name, Filgrastim.

Neupogen is a colony stimulating factor, or substance that induces the bone marrow to produce more white blood cells. Neupogen is believed to work by stimulating the production of white blood cells, which fight infection and fever.

How do I take it?
Prescribing information states that Neupogen should be administered once a day via a subcutaneous injection or intravenous infusion.

Neupogen comes in prefilled syringes or vial.

Side effects
The FDA-approved label for Neupogen lists common side effects including diarrhea, anemia, mouth pain, fatigue, swelling of the extremities, malaise, decreased appetite, and hair loss.

Rare but serious side effects listed for Neupogen can include systemic allergic reactions, kidney problems, acute respiratory distress, and rupture of the spleen.

For more information about this treatment, visit:

Neupogen - Amgen
https://www.neupogenhcp.com/